<DOC>
	<DOC>NCT00322439</DOC>
	<brief_summary>This is an observational safety study tracking psoriasis patients on etanercept (Enbrel) for 5 years.</brief_summary>
	<brief_title>Observational Safety Study of Etanercept (Enbrel) for Treatment of Psoriasis</brief_title>
	<detailed_description>This is a prospective, multi-center, observational surveillance registry to evaluate data on the long-term safety of etanercept (Enbrel) use in the treatment of psoriasis.</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Patients with plaque psoriasis Prior exposure to any tumor necrosis factor (TNF)inhibitor Patients for whom Enbrel is contraindicated Patients currently enrolled in or has not yet completed at least 30 days since ending other investigational drug study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>plaque Psoriasis patients</keyword>
	<keyword>TNF-inhibitor na√Øve</keyword>
</DOC>